Objective To investigate the therapeutic effect of exosomes extracted from human adipose-derived mesenchymal stem cells(hAMSCs) on traumatic brain injury (TBI) and its possible mechanism.Methods Mesenchymal stem cells(MSCs) were isolated from healthy human adipose tissue and the exosomes were extracted by ultrafiltration.Rats were divided into four groups: sham group, PBS control group, MSCs treatment group and exosomes treatment group.24 h After TBI, the treatment group was locally injected along the lesion area, 30 μL of PBS, 2×105 MSC, 25 μg protein of exosomes respectively, the total volume was 30 μL.We performed the Modified Neurological Severity Score(mNSS) and the forelimb Foot-Fault Test in all rats before injury and at 1, 3, 7, 10, 13, 16, 21 and 30 days after TBI.The rats were sacrificed at 3 and 7 days after TBI respectively,total RNA was extracted from rat brain tissue.The expression of TNF-α and IL-1β were detected by quantitative PCR.The rats were also killed at 30 days after TBI for testing the neuronal apoptosis in lesion area by tunel-neun double imm-unofluorescence.Results Exosomes treatment significantly promotes the recovery of neurological deficits caused by TBI,and the therapeutic effect is similar to MSCs, its possible mechanism may be the inhibition of the acute inflammation and the reducing of the neurons apoptosis after TBI.Conclusions Exosomes extracted from human adipose-derived mesenchymal stem cellshas promoted neurological functionrecovery after traumatic brain injury, which will provide a new and safer TBI treatment for clinical practice.

Pharmaconutrients refer to macronutrients,micronutrients,microecologics,and nucleotides.Informed by large randomized clinical trials,people have become increasingly prudent in using pharmaconutrients.Critically-ill neurological patients are intensive care patients who have neurological impairment,and therefore command extra caution in using pharmaconutrients.This article reviews the latest studies on the use of pharmaconutrients in this group of patients.

Objective:To analyze the clinical features, treatment, pathology and prognosis of retroperitoneal paraganglioma(PGL).Methods:Surgery adopted, pathology and follow-up data of patients with retroperitoneal PGL at the First Affiliated Hospital of Zhengzhou University from Jan 2015 to Jan 2022 were retrospectively analyzed.Results:Compared with non-functional PGL patients, those with functional PGL had higher systolic and diastolic blood pressure (180 mmHg vs. 140 mmHg, Z=-4.807, P<0.001;100 mmHg vs. 82 mmHg, Z=-4.495, P<0.001)at admission, and were more prone to hemodynamic instability during operation ( χ2=8.188, P=0.004). All 65 patients under wentresection,with partial excision and repair of inferior vena cava in 1 patient . Sixty-two patients out of 65 were followed up, and 4 patients died of disease progression. The overall 5-year survival rate was 92%. The prognosis of patients with G3 tumor and distant metastasis was poor , the difference was statistically significant ( χ2=4.259, P=0.039; χ2=13.061, P<0.001). Tumor diameter and tumor functional status were not related to the prognosis, and the difference was not statistically significant ( χ2=0.519, P=0.472; χ2=0.010 P=0.920). Conclusions:Retroperitoneal PGL is less common, and some may encroach abdominal large vessels. The prognosis is good after complete resection of the tumor. Distant metastasis and G3 tumors are associated with poor prognosis .